A biologics license application has been submitted to the FDA by Amgen for its erenumab as a prevention drug for migraine. Erenumab will be co-promoted with Novartis' CGRP receptor inhibitor if approved by the agency.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.